Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Kite, A Gilead Company.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic Malignancies

Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic Malignancies




This live webcast will air on 24 May, 2018 at 18:00 Central European Time (CET).

For US viewers, the live webcast will begin at 12:00pm EST.

Overview

Join us online for Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic Malignancies, a live-stream, interactive broadcast featuring international experts in the field of hematologic malignancies who will bring you key insights into the clinical application of chimeric antigen receptor (CAR) T-cell therapy. For patients with leukemia or lymphoma, stem-cell transplantation (SCT) provides the best chance of long-term remission; however, not all patients are eligible, and patients who relapse after SCT have a poor prognosis. This has led to the development of therapies with nonoverlapping mechanisms of action, such as CAR T cells.

We would be delighted for you to take part in this exciting event, where we will offer education to augment your foundation of knowledge and clinical competence in several areas, including:

  • The unique mechanism of action of CAR T cells
  • Clinical considerations for the use of CAR T cells and differentiation from chemotherapy and targeted therapy
  • Data demonstrating durable complete responses in patients with heavily pretreated B-cell acute lymphoblastic leukemia or aggressive B-cell lymphoma
  • Managing adverse events associated with CAR T cells

 
Virtual Current Trends program is an in-studio panel discussion where experts discuss and debate key concepts and clinical applications in oncology. In addition, you will have multiple opportunities to engage with the faculty through submission of questions and/or cases to be discussed by the panel during the live session. Register today and bring medical conference‒caliber education to the convenience of your screen!

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Kite, A Gilead Company.

Target Audience

This educational activity is directed towards Ex-US clinicians including medical oncologists, hematologists, and fellows who treat patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies will be invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Explain the mechanism of action of CAR-T cells in hematologic malignancies and differentiate among available and emerging therapies
  • Describe the manufacturing of CAR-T cells and the standards under which manufacturing is conducted
  • Discuss recent clinical trial data concerning the application of CAR-T cell strategies in the context of evolving treatment paradigms for hematologic malignancy management
  • Delineate appropriate techniques to identify and manage different treatment-related toxicities in the care of patients who receive CAR-T cell therapies


Moderator

Paolo Ghia, MD, PhD
Associate Professor
Università Vita-Salute San Raffaele
Director, Strategic Research Program on CLL
IRCCS San Raffaele Scientific Institute
Milan, Italy







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
30
Filter By